accountin niche market opportunities in serious CNS or brain disorders, in addition to more common diseases, such as Alzheimer's disease and schizophrenia. Several promising disease targets in addition to PSP have been identified and are currently being...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to FDA Grants Orphan Drug Designation For Mithridion's MCD-386CR To Treat Progressive Supranuclear Palsy
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account